webinar
Hit discovery for GPCRs: HTS or virtual screens?
8 April 2021 | By Beacon Discovery
Watch our on-demand webinar and learn from an industry expert regarding GPCR virtual screening approaches and challenges and much more.
List view / Grid view
Targets
news
Dynamic model of SARS-CoV-2 S protein reveals vaccine targets
A model of the SARS-CoV-2 Spike protein surface has uncovered vulnerabilities that researchers say could inform the development of COVID-19 vaccines.
news
Team reveals miR-29 as regulator of processes for normal brain maturation
Researchers have shown that miR-29 can control brain maturation in mammals, presenting a target for autism, epilepsy and other conditions.
whitepaper
Article: Defeating COVID-19: The science behind a new ELISA
Discover how a new ELISA against S1-RBD for COVID-19 seroconversion detection can accelerate discovery to facilitate vaccine breakthroughs.
news
Revealed structure of enzyme could progress cancer research
Researchers have elucidated the 3D structure of the Taspase 1 enzyme, known to be involved in a range of cancers.
news
Inhibiting Asc-1 protein function could present new drug target for obesity
Researchers have shown that loss of Asc-1 function could help obese patients maintain a healthy metabolism.
news
Novel opioid could provide pain relief alternative to fentanyl
NFEPP, a new opioid, inhibited colon pain in mice with colitis but did not cause the side effects associated with use of fentanyl.
article
Fighting HIV: could antibodies be the answer?
Although a cure for HIV continues to elude scientists, strategies to control the virus and immunise people are developing at rapid pace. Here, Drug Target Review’s Victoria Rees discusses why researchers are focusing on antibodies as approaches to combat HIV and highlights recent findings from two pre-clinical studies into how…
news
Tumour cell vaccine strategy developed for neuroblastoma and melanoma
A combination of checkpoint and small molecule inhibitors showed success at targeting Myc oncogenes in mouse neuroblastoma and melanoma models.
article
Immunosurveillance and the importance of CD4 T cells in developing cancer vaccines
In this article, Dr Lien Lybaert describes how the innate and adaptive immune system work together to produce an effective and durable antitumour response. She explains why the best strategy for personalised cancer therapy is therefore to identify major histocompatibility (MHC) binding epitopes to cover the full antigenic repertoire of…
article
Glycolytic-pathway inhibition and CTLA-4 blockade to improve immuno-oncology
In this Q&A, Dr Taha Merghoub discusses how a combination of glycolytic-pathway inhibition and immune checkpoint blockade using anti-CTLA-4 in patients with highly glycolytic tumours could present a personalised approach for immuno-oncology.
article
Developing a broadly neutralising antibody therapeutic to combat SARS-CoV-2
With the ongoing COVID-19 pandemic, new treatments continue to be urgently needed. One potential solution is antibody therapeutics, which can be used to neutralise the coronavirus and provide future immunity to patients. Here, Dr Laura Walker from Adagio Therapeutics discusses how antibodies can be used in the fight against Severe…
article
The development of biomaterial-based vaccine platforms against viruses
Recent years have seen an increase in the development of biomaterial and nanoparticle-based vaccine formulations. Sushma Kumari, Sonal Asthana and Kaushik Chatterjee from the Department of Materials Engineering at the Indian Institute of Science discuss why these materials have such high potential in the fight against infectious diseases.
article
Drug Target Review Vaccine Development ebook 2021
This ebook includes articles discussing why biomaterial and nanoparticle-based formulations could lead to the next generation of vaccines and exploring how a new rhinovirus vaccine showed promise in pre-clinical studies.
article
Broad T-cell responses: designing a rhinovirus vaccine
The multiple serotypes of rhinovirus have presented difficulties for vaccine developers. Now, a team led by Professor Gary McLean from London Metropolitan University and Imperial College London, alongside Professor Sebastian Johnston from Imperial, has formulated a potential vaccine. Nikki Withers spoke to McLean to discover how the vaccine works and…
